Armephaco JSC

Armephaco JSC Equity Growth

The Year-over-Year Equity Growth of Armephaco JSC (AMP.VN) as of Nov 16, 2026 is 2.00 %. In the previous year, Year-over-Year Equity Growth was 18.29 % — a change of -89.09% (lower).

Equity Growth

2.00 %

YoY

-89.09%

Last updated:

Year-over-Year Equity Growth of Armephaco JSC is 2025 2.00 % . Year-over-Year Equity Growth of Armephaco JSC was 2024 18.29 % . It decreases by -89.09% lower compared to the previous year.

The Armephaco JSC Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2018
3.51 VND
Jan 1, 2019
3.82 VND
Jan 1, 2020
3.47 VND
Jan 1, 2021
2.33 VND
Jan 1, 2022
-1.75 VND
Jan 1, 2023
-11.74 VND
Jan 1, 2024
18.29 VND
Jan 1, 2025
2.00 VND
The Armephaco JSC Equity Growth history
YEAREquity GrowthYoY
2.00 %-89.09%
18.29 %-255.74%
-11.74 %+571.93%
-1.75 %-175.08%
2.33 %-33.02%
3.47 %-8.96%
3.82 %+8.60%
3.51 %-3.58%
3.65 %-18.01%
4.45 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Armephaco JSC Stock analysis

What does Armephaco JSC do? Armephaco JSC manufactures pharmaceutical and medical equipment products, focusing on glucose meters, sphygmomanometers, beds, medical exam tables, stools, and syringe destroyers. The company distributes medical devices and equipment through its manufacturing and distribution channels, targeting healthcare providers and hospitals. It also produces and trades diversified medicines, including antibiotics, vitamins, pain relievers, antipyretics, gastrointestinal, and anti-allergic drugs, serving the broader healthcare market. The firm generates revenue from the sale of medical devices and equipment, as well as from pharmaceutical products. Healthcare providers and hospitals purchase the medical devices and equipment, while the diversified medicines are sold to pharmacies and healthcare institutions. Armephaco JSC's product portfolio includes glucose meters, sphygmomanometers, beds, medical exam tables, stools, syringe destroyers, antibiotics, vitamins, pain relievers, antipyretics, gastrointestinal, and anti-allergic drugs. Armephaco JSC's business model centers on the production and distribution of medical devices and pharmaceuticals. The company's primary customers are healthcare providers, hospitals, pharmacies, and healthcare institutions. The revenue streams are derived from the direct sale of medical equipment and pharmaceutical products to these segments, with no mention of additional services or partnerships. Armephaco JSC is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Armephaco JSC stock

Year-over-Year Equity Growth of Armephaco JSC is 2.00 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Armephaco JSC since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Armephaco JSC historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Armephaco JSC

All Key Metrics — Armephaco JSC